The purpose is to find out whether AST-004 can protect the brain and be safe for patients with this type of injury. Participants will receive a single infusion of either the study drug or the placebo shortly after their injury, remain in the hospital for a brief observation period, and then attend a few follow‑up visits over roughly one month.

During the follow‑up, blood samples will be taken to measure a protein called GFAP that indicates brain cell damage, and a special brain scan using MR spectroscopy will be performed to examine brain chemistry. Researchers will monitor for any side effects and record changes in how patients feel and function.

The purpose of the study is to compare survival rates in the hospital between patients who receive propranolol and those who receive placebo. The study will look at whether propranolol can help reduce the number of deaths that occur in the hospital among patients with traumatic brain injury who are admitted to the intensive care unit. The study will also examine the overall recovery and functional outcome of patients using a measurement scale that assesses how well patients are able to function after their injury.

Patients can be enrolled in the study within the first 96 hours after their injury occurs. Before treatment begins, patients must be in stable condition with adequate blood pressure, heart rate, and blood flow to the brain. The treatment will continue for 14 days with a maximum daily dose of 240 milligrams. Patients or their legal representatives must provide consent to participate in the study. The study is designed so that neither the patients, their doctors, nor the researchers know which treatment is being given during the study period.

After a short period of daily dosing, participants are monitored over the course of up to a year. Follow‑up visits include checks of vital signs, blood tests, a brain scan using MRI, and a heart rhythm test called a ECG. Functional recovery is assessed with a questionnaire called the Glasgow Outcome Scale – Extended, which helps gauge the ability to perform everyday activities. Throughout the study, any side effects or health problems are recorded, and participants may stop the treatment if it becomes intolerable. The study concludes after the final follow‑up assessment.

The study will use two treatments: sodium chloride solution and mannitol solution, both given through an intravenous line. These medications help control the pressure inside the brain after injury. Patients will receive treatment for up to 7 days while being monitored in an intensive care unit.

The study will track how well patients recover over time, particularly focusing on their survival after 3 months and their ability to perform daily activities independently after 6 months. Doctors will monitor various aspects of patient health, including salt levels in the blood and kidney function, to ensure the treatment is safe. The evaluation of how well patients recover will be done by medical professionals who do not know which treatment the patient received.

The purpose of the study is to explore the metabolic changes in the brain’s dopamine network in patients who have experienced a traumatic coma. Participants will receive the [18F]LBT-999 injection, and then undergo a PET scan to observe how the agent binds to dopamine transporters in the brain. This will help researchers compare the brain activity of patients with traumatic coma to those without such injuries. The study will also look at how these changes relate to the patient’s recovery and overall brain function over time.

Throughout the study, participants will be monitored at different intervals, including 3 months, 6 months, and 1 year after the initial brain injury. This will help assess their neurological recovery and quality of life. The study aims to provide valuable insights into the recovery process of patients with severe traumatic brain injuries and potentially improve future treatment approaches.

The treatment involves giving patients either mesenchymal stromal cells or a placebo. Two different amounts of cells will be tested: 80 million cells or 160 million cells. The treatment must be given within 48 hours after the brain injury occurs. During the study, doctors will monitor changes in the brain using special blood tests and magnetic resonance imaging (MRI) scans.

Patients will be followed for one year after receiving the treatment. Throughout this time, doctors will check how well the brain is healing and monitor the patient’s recovery progress. They will use various tests to measure improvements in brain function and overall quality of life. The study will help determine if this new cell treatment can reduce brain damage in people who have experienced severe head injuries.

The purpose of the study is to evaluate the effectiveness and safety of Cerebrolysin in helping with recovery after a moderate to severe traumatic brain injury. Participants in the study will be monitored over a period of time to assess their recovery and any changes in their condition. The study will look at various outcomes, including the participants’ neurological function, symptoms of anxiety and depression, and overall quality of life at different points in time, such as 10, 45, 90, and 180 days after starting the treatment.

Throughout the study, participants will receive regular assessments to track their progress and any side effects they may experience. The main goal is to determine how well Cerebrolysin works in improving recovery and to ensure it is safe for use in people with traumatic brain injuries. This research aims to provide valuable information that could help improve treatment options for individuals affected by this condition.

Participants in the study will receive either ketamine or a placebo as part of their treatment. Ketamine is administered as a solution for injection, specifically through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The study will monitor the effects of ketamine on the pressure inside the skull and the overall treatment intensity required for managing this pressure.

The trial will follow participants over a period of time to observe any changes in their condition, including the number of high-pressure episodes and the duration of sedative treatments. The study will also look at other factors such as the length of stay in the intensive care unit and the hospital, as well as the overall recovery outcomes six months after the brain injury. The goal is to determine if ketamine can make a significant difference in the treatment and recovery of patients with traumatic brain injury.

The purpose of the study is to evaluate the safety and effectiveness of the C1 Esterase Inhibitor in patients with traumatic brain injury. Participants in the study will receive either the C1 Esterase Inhibitor or a placebo, and their progress will be monitored over a period of time. The study aims to understand how well the treatment works in reducing inflammation and improving outcomes after a traumatic brain injury.

Throughout the study, participants will be closely observed to track any changes in their condition and to identify any potential side effects. The study will use various scales and assessments to measure the intensity of therapy required and the overall recovery of the participants. The goal is to gather valuable information that could lead to better treatment options for those affected by traumatic brain injuries in the future.